the top ten companies in india in biotechnology

1) SERUM INSTITUTE OF INDIA


COMPANY BACKGROUND:-

Serum Institute of India Ltd. has established it's self as the world's largest producer of Measles and DTP group of vaccines. It is estimated that 2 out of 3 children immunized in 2004, with a vaccine, received one manufactured by Serum Institute. In fact, our ranges of products have been used in 145 countries across the globe.
Serum Institute of India was founded in 1966 with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man and in abundance, with the result that the country was made self-sufficient for Tetanus Anti-toxin and Anti-snake Venom serum, followed by DTP (Diphtheria, Tetanus and Pertussis) group of Vaccines and then later on MMR (Measles, Mumps and Rubella) group of vaccines.

The Philanthropic philosophy of the company still not only exists but has been proliferated to bring down the prices of newer vaccines such as Hepatitis-B vaccine, Rabies vaccine, Combination vaccine etc., so that not only Indian, but the entire under-privileged children of the world, in more than 145 countries are protected from birth onwards.

Serum Institute of India have recently set up Serum Bio Pharma Park, India's first biotech Special Economic Zone (SEZ). The Park is adjoining Serum Institute's existing manufacturing unit and is a sector-specific SEZ meant for biotechnology and pharmaceutical products. The SEZ will allow Serum Institute of India to avail various tax benefits such as income tax, import duty on capital goods etc. This has encouraged a lot of foreign companies to partner with Serum Institute of India to avail and share these benefits.

Serum Institute is recognized as a reliable source of High Quality vaccines and biologicals. Our products have been supplied to International Health Agencies like the WHO, UNICEF, PAHO and also to more than 145 countries. The high service standards have resulted in several acknowledgements and appreciation from International agencies and local governments and awards from Trade authorities.
We are proud that our vaccines are being used in the National Immunization Programmes of several countries. The MR vaccine is being used in catch-up and mop-up campaigns of several countries in their quest to control the incidence of measles and rubella. With the launch of the DTP-HB Combination Vaccines, Serum Institute will, without doubt, play a significant role in controlling the four dreaded diseases and bringing comfort to millions of children the world over, including the underprivileged.


GROWTH:-

Several official awards and marks of recognition have been showered on Serum Institute of India.
Certificate of Merit awarded by CHEMEXCIL, Mumbai, for outstanding export performance in 1994-95.
First Award under the Drugs and Pharmaceuticals panel from CHEMEXCIL, Mumbai, for sterling export performance in 1995-96.
Certificate for Export Recognition (1st Rank) under the Export House category, from the Government of Maharashtra for export achievement in 1996-97.
Vikas Bharati Award received in 1997 from International Council for Business Promotion, New Delhi, for outstanding achievements and contribution in the chosen field of activities, towards promotion and maintaining quality and standard of products/ services through innovative strategies.
Certificate of Merit awarded by the Government of India, Ministry of Commerce for outstanding export performance in 1996-97.
Export Excellence Award for 1996-97 and 1997-98 awarded to TOP TEN EXPORTERS from Pune Region by the Joint Director General of Foreign Trade, Pune and Maratha Chamber of Commerce, Industries and Agriculture.
PRODUCTS:-
Manufactured Products

Bacterial Vaccines
BCG Vaccine BCG Vaccine I.P.
Tetanus Vaccine Tetanus Toxoid Vaccine (Adsorbed) I.P.
Dual AntigenDiphtheria and Tetanus Vaccine (Adsorbed) I. P.
Triple AntigenDiphtheria, Tetanus & Pertussis Vaccine (Adsorbed) I.P.

Viral Vaccines
SII Rabivax®Rabies Vaccine U.S.P.
M-VacMeasles Vaccine Live I.P. (Lyophilised)
TresivacMeasles, Mumps & Rubella Vaccine Live U.S.P. (Lyophilised)
R-VacRubella Vaccine Live B.P. (Lyophilised)

Recombinant & Combination Vaccines
Gene Vac-B®Recombinant Hepatitis-B Vaccine I.P.
SII Q-Vac (Quadrivalent Vaccine)®Diphtheria, Tetanus, Pertussis & Hepatitis-B Vaccine (Adsorbed)
Anti-cancer Products
Doxorubicin Hydrochloride Injection I.P. (Lyophilized) 10 mg & 50 mg
Cisplatin Injection B. P. (Lyophilised) 10 mg / 10ml , 25 mg / 25 ml & 50 mg / 50 ml
Vincristine Sulphate Injection I.P. (Lyophilised) 1 mg, 2 mg & 5 mg
Etoposide Injection U.S.P. 100 mg / 5 ml
Carboplatin for Injection U.S.P. (Lyophilised) 150 mg
Dacarbazine for Injection U.S.P.(Lyophilised) 200mg
Bleomycin for Injection U.S.P. (Lyophilised) 15 units
Amphotericin B for Injection U.S.P. (Lyophilised) 50 mg
Cyclophosphamide for Injection U.S.P. (Lyophilised) 100 mg, 200 mg, 500 mg & 1 gm
Methotrexate Injection B.P. 25 mg/ml - 2 ml and 10 mg/ml - 5 ml

Anti Sera, Plasma & Hormonal Products
Sii Polyvalent Anti Snake Venom SerumSnake Antivenom Serum, I.P. (Lyophilised)
Sii Somastin 250 & 3000Somatostatin Injection 250 mcg & 3 mg (Lyophilised)

Marketed Products

Serono Products
lGonal-f ® 5.5 mcg, 44 mcg & 87 mcg Multi-dose vials Follitrophin alfa (r-hFSH) (Lyophilised)

Luveris® 75 IULutropin alfa
Ovidrel® 250 mcgChoriogonadotropin alfa
Cetrotide® 0.25 mgCetrorelix acetate
Crinone®Micronised Progesterone Vaginal gel
Rebif® 44 mcgInterferon beta-1a
Saizen® 10 IUSomatropin (r-hGH) (Lyophilised)

Hormonal Products
Siphene ® 50 mg, 100 mg & Siphene-M 25 mg.Clomiphene Citrate tablets U.S.P.
Sicriptin® 1.25 mg & 2.5 mgBromocriptine Mesylate Tablets I.P.
CB-Lin® 0.5 mg & 1 mgCabergoline Tablets.
Zendol® 50 mg, 100 mg & 200 mgDanazol Capsules I.P.
Meprate® 10 mg, 2.5 mgMedroxyprogesterone Acetate Tablets U.S.P.
Sibolone® 2.5 mgTibolone Tablets
Other Pharma Products
Limarin™ 70 & 140 mg Capsules, Suspension 35 mg / 5 ml Silymarin (Hepatoprotective)
SD-15 Tablets Serratiopeptidase 15 mg & Diclofenac 75mg (sustained release)
SN-15 Tablets Serratiopeptidase 15 mg & Nimesulide 100 mg tablets
SN-15 Gel Diclofenac, Mephenesin, Methyl salicylate, Oleum lini & Methol
PyginalPygeum Africanum Soft Gelatin Capsules
Dipep Capsules & SuspensionDigestive enzyme preparations
Hemsi Capsules, Syrup & DropsHaematinics
Logi-Cal M, Logi-Cal 250 mg, 500 mg Tablets & Logi-Cal Suspension (150 mg/5ml)Calcium supplements
SinateDoxylamine succinate, Pyridoxine & Folic acid Tablets
RADO-TR CapsulesRabeprazole Sodium20 mg (enteric coated pellets), Domperidone B.P. 30 mg (controlled release)




Exported Products
Vaccines & Anti-cancer products meet WHO specifications & various pharmacopoeias
Bacterial Vaccines
BCG Vaccine (Lyophilised)
Tetanus ToxoidAdsorbed Tetanus Vaccine
Dual Antigen Adsorbed Diphtheria & Tetanus VaccineAdsorbed Diphtheria & Tetanus Vaccine for adults & adolescents
Triple Antigen Adsorbed Diphtheria, Tetanus & Pertussis Vaccine
Viral Vaccines
Hepatitis-B Vaccine (rDNA)Pediatric strength & Adult Strength
Measles Vaccine (Lyophilised)
Rubella Vaccine (Lyophilised)
Measles and Rubella Virus Vaccine (Lyophilised)
Measles, Mumps and Rubella Virus Vaccine (Lyophilised)
Rabies Vaccine (Liquid)
Combination Vaccine
Diphtheria, Tetanus, Pertussis & Hepatitis B VaccineAdsorbed
Anti-sera
Sii Polyvalent Anti - Snake Venom SerumSnake Antivenom Serum (Lyophilised)
Sii Polyvalent Anti - Snake Venom SerumSnake Antivenom Serum (Lyophilised) (Central Africa)
Tetanus Antitoxin1500 IU, 10000 IU, 20000 IU, 25000 IU, 50000 IU
Diphtheria Antitoxin1000 IU, 2000 IU, 10000 IU
Rabies Antiserum1500 IU/5 ml, 1000 IU/ 5ml
Anti-cancer Products
Doxorubicin Hydrochloride Injection(Lyophilised) 10 mg & 50 mg
Cisplatin Injection10 mg / 10ml , 25 mg /25 ml & 50 mg / 50 ml.
Vincristine Sulphate Injection(Lyophilised) 1mg, 2 mg & 5 mg
Etoposide Injection100 mg / 5 ml
Carboplatin for Injection(Lyophilised) 150 mg
Dacarbazine for Injection(Lyophilised) 200 mg
Bleomycin for Injection(Lyophilised) 15 units
Amphotericin B for Injection(Lyophilised) 50 mg
Cyclophosphamide for Injection(Lyophilised) 100 mg, 200 mg, 500 mg & 1 gm
Methotrexate Injection25 mg/ml - 2ml; 10 mg/ml - 5 ml
Epirubicin Hydrochloride for Injection(Lyophilised) 10 mg, 50 mg & 25 ml (liquid)
5-Flurouracil Injection10 ml / 25 ml / 50 ml



























2) BIOCON


COMPANY BACKGROUND:-

Established in 1978, Biocon Limited is India's premier biotechnology company. Headquartered in Bangalore Biocon has evolved from an enzyme company to a fully integrated biopharmaceutical enterprise, focused on healthcare.
Biocon and its two subsidiary companies, Syngene International Limited and Clinigene International Limited forms a fully integrated biotechnology enterprise specializing in biopharmaceuticals, custom research, clinical research and enzymes. Biocon's integrated business approach has enabled the company to establish a significant presence in the global biopharmaceutical market via its product offerings and customised, high value solutions at any stage in the lifecycle of a drug-from discovery to market. Biocon’s vision is to be an integrated biopharmaceutical enterprise of global distinction.
The company applies its proprietary fermentation technologies to make effective and innovative biomolecules in diabetology, oncology, cardiology and other therapeutic segments. Biocon's products in the biopharmaceutical category includes: anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-oxidants, biologicals, cholesterol-lowering agents, digestive-aid enzymes, haemostatic agents, hepatoprotective agents, immunosuppressants, nutraceuticals and orthopaedic agents. Products in the enzymes category include: amylases, cellulases, esterases, hemicellulases/ xylanases, oxidases, pectinases, proteases and tannase.
With its strong focus on R&D Biocon offers services in custom research (Syngene) in the fields of synthetic chemistry and molecular biology in early stage drug discovery and development. Clinical research (Clinigene) is carried out in the fields of clinical studies and clinical trials.
Biocon Park, inaugurated in June 2006 by President APJ Abdul Kalam comprises an integrated cluster of research laboratories and manufacturing facilities laid out on a 90 acre expanse in Bommasandra Industrial Area – Phase IV. Built with a total investment of Rs. 650 crores, with further investments to follow, Biocon Park is the single largest capital investment made by Biocon in its 27-year history and is focused on exports of both bio-pharmaceutical products and research services. The multi-product facilities mainly cater to the following disease segments: cardiovascular, cholesterol reduction, immunosuppressants in organ transplantation, diabetes and cancer.
Biocon's success has been characterized by an enduring set of corporate values based on innovation, integrity, strong leadership and social responsibility. As India's first and leading biotechnology company Biocon extends its support to numerous community outreach and corporate citizenship initiatives with special concentration in the areas of healthcare, education and environment. The Biocon Foundation, set up in 2004 has launched Arogya Raksha Yojana, a unique health initiative for rural India.
Biocon aims to continuously create growth in different areas of the company and is the first company, globally to manufacture human insulin, InsugenTM , using a Pichia expression system. In addition, Biocon is India's largest producer of human insulin andis positioned to beIndia’s first company to set up commercial production of monoclonal antibodies.
GROWTH:-

Biocon’s FY 2006-2007 Performance Shows healthy Growth
Revenues Rs.990 crs : EBITDA Rs. 287 crs : PAT Rs.200 crs
- Total income increases by 25% to Rs. 990 crores.
- Operating margines by 29% for the year.
- PAT increases 15% to Rs.200 crores.
- Earnings per share at Rs.20 for the year.
- R&D revenue expenditure increases by 88% to Rs.38 crores.
- Dividend increase from 50% to 60% (Rs.3/-per share ) recommended by the board.
- Q4 2006-2007 shows a 30% top line growth (Rs.279 crores vs Rs.215 crores ) and
27% growth in PAT (Rs.61 vs Rs.48 crores) over the corresponding quarter for the
Last fiscal.




PRODUCTS:-
Biocon’s fully integrated business model spans the entire drug value chain, from pre-clinical discovery to clinical development and through to commercialisation. Our businesses in custom research (Syngene), clinical development (Clinigene) and biopharmaceuticals (Biocon) provide multiple revenue streams to balance risk, drive innovation, deliver products and accelerate growth. As we increase the complexity and scope of our own R&D and manufacturing operations, especially in new product discovery and development, we believe our custom and clinical research services will continue to offer important synergies.
Syngene : Pre-Clinical DiscoveryBiocon’s custom research organisation, Syngene, offers high value discovery and development services, from target identification and validation to small molecule and library synthesis. With our reputation for meticulous IPR protection, we provide pharmaceutical and biotechnology majors customised solutions in the areas of synthetic chemistry and molecular biology.
Clinigene : Clinical Development Biocon’s clinical research organisation, Clinigene, specialises in Phase I-IV clinical trials and studies, using well-characterised clinical databases in diabetes, oncology, lipidemia and cardiovascular diseases. We offer these services at our CAP and NABL accredited Central Reference Laboratory and a state-of-the-art Bioavailability and Bioequivalence (BA/BE) Centre.
Biocon : CommercialisationBiocon has an impressive track record of commercialisation capabilities. We have brought to market a considerable portfolio of biopharmaceuticals, led by our blockbuster Statins. The commercialisation of Insulin, Immunossuppressants and a range of Biogenerics demonstrates our highly advanced process development and manufacturing expertise. Under rapid progress are two challenging collaborative projects for the development of novel medicine, including Oral Insulin and T1h. Biocon also markets a basket of branded formulations in India, among them INSUGEN®, BIOMAb EGFR™ and EPO.














3) PANCEA BIOTECH

COMPANY BACKGROUND:-
Panacea Biotec manufactures and markets branded vaccines, pharmaceutical and biotechnology-based products of international quality and has emerged as a leading health management company of India. Panacea Biotec is amongst Top 50 Pharmaceutical Companies in India. Business World 500 Survey ranks Panacea Biotec at 18th rank in the industry. Economic Times 500 survey ranks Panacea Biotec in Top 5 on the basis of RONW. The manufacturing plant for vaccines in New Delhi is prequalified by WHO for supply to UN Agencies. The company started focusing on biological and biotechnology based products in 1993, in addition to pharmaceutical formulations. With a special focus on biotechnology, Panacea Biotec has been making concerted efforts to improve the repertoire of its vaccines. A host of new vaccines employing genetic engineering and recombinant technology are being developed. The Hepatitis B vaccine- Enivac HB is being manufactured in collaboration with CIGB (Center for Genetic Engineering and Biotechnology), Havana, Cuba- a world leader in biotechnology. Panacea Biotec has recently developed several combination vaccines, some of the leading ones are Ecovac (DPT+HepatitisB), Easy Four (DPT+Hib) and Easy Five (DPT+HepatitisB+Hib). Few of the promising vaccines under different phases of development are Anthrax Vaccine (recombinant) & Japanese Encephalitis Vaccine. Panacea Biotec has recently formed a joint venture with Chiron Vaccines, a U.S. based $ 5 billion multinational company, to market vaccines in India. Panacea Biotec has developed thermostable vaccines in collaboration with Cambridge Biostability, a U.K. based research company. The new "stable liquid" technology makes vaccines stable across a range of temperature thus removing the need for the cold chain. This will enable the children, even in remote areas, to receive economical and safer immunisation from preventable killer diseases. The collaborations with Chiron Vaccines (U.S.) and Cambridge Biostability (U.K.) provide a significant advantage to Panacea Biotec to speedily progress in the field of biotechnology in coming years. Panacea Biotec has more than 150 scientists in 3 state of the art R&D centers in the field of Pharmaceuticals, Biopharmaceuticals and Vaccines. The company has recently built it's 4th R&D center in Drug Discovery at Mohali near Chandigarh (Punjab).Research & Development
Ardent Research and Development efforts have always been a great strength of Panacea Biotec. The company has spent 6.14 % of it's net sales on R&D last year, an increase of 34 % over previous year. The increased R&D expenditure is in line with the company’s strategy of expanding its scientific strength by working tirelessly to find novel therapies and drug delivery systems aimed to establish leadership in target segments.
Panacea Biotec is ranked 6th among pharmaceutical companies in India by ET 500 for its spending ratio on R&D.
Panacea Biotec with 200 scientists working in two state-of-the-art R&D centers in New Delhi and Lalru, Punjab, has developed some of the most exclusive products based on the novel drug delivery systems which have been patented worldwide .In the field of Vaccines , Panacea Biotec has to its credit development of Monovalent Type 1 Oral Polio Vaccine ( mOPV1 ) in addition to the conventional Trivalent Oral Polio Vaccine and new innovative Combination Vaccines.
Going forward , the company is in process of having a pentagon of 5 R & D centers and 500 scientists . Three new Research & Development centers in the process of commissioning are :
· New Drug Discovery Research centre at Mohali, Punjab, to develop New Chemical Entities.
Biopharmaceutical Research Centre in New Delhi, focusing on novel vaccines, peptides & monoclonal antibodies.
Global Research & Development Centre (GRAND) at Navi Mumbai, to develop advanced drug delivery research based products.
Panacea Biotec has recently entered into an in-licensing arrangement with National Institute of Health, USA for the use of peptide based product for generation of hair follicles and hair growth. The commercialization of the product will benefit those individuals afflicted with alopecia (baldness) including androgenetic alopecia.
Panacea Biotec has entered into strategic collaboration with UK based Cambridge Biostability LTD. for manufacturing of vaccines in India using ‘stable liquid’ technology which reformulates existing vaccines into ready-to-inject stable liquids and will revolutionize vaccine delivery by eliminating the need for refrigeration. The technology will be developed and commercialized by Panacea Biotec for the first time in the world and will save lot of costs associated with maintaining cold chain for distribution of vaccines and loss caused due to wasted vaccines each year.
Panacea Biotec has a 50:50 joint venture with UK based Chiron Vaccines. The new joint venture company, Chiron Panacea Vaccines, will focus on providing new breakthrough vaccines in India. This strategic alliance will provide India with a key competitive advantage in providing new generation combination vaccines to help prevent life threatening infectious diseases. The present portfolio of vaccines being marketed by Chiron Panacea Vaccines are Enivac HB ( hepatitis B ) , Enivac HB safsy ( Hepatitis B Vaccine in Auto- disable device ) , Ecovac 4 ( tetravalent vaccine – DTwP- Hep B) , Easy Four ( DTwP-Hib) and Easy Five ( DTwP- HepB-Hib ) Panacea Biotec also has a JV with a Cuban company to produce biotechnology-based vaccines. Panacea Biotec also has a license agreement with Biotechnology Consortium of India (BCI) for the manufacture & marketing of anthrax vaccine developed by Jawaharlal Nehru University, New Delhi.Besides, the company has entered into arrangement with National Institute of Immunology (NII), New Delhi for licensing of technology and processes for the production of tissue culture-derived, formalin-inactivated Japanese Encephalitis Candidate Vaccine.
GROWTH:-
Panacea Biotec has recorded a remarkable performance during quarter & nine months ended 31st December 2006 and achieved a record turnover of Rs. 6112.2 million, a growth of 48.9% as compared to Rs. 4105.0 million during the corresponding previous year. Earning before interest depreciation and tax during the period was Rs. 2171.9 million, as against Rs 999.5 million in the corresponding previous year, up by 117.3%. Profit before tax during the period rose to a record high of Rs. 1804.6 million as against Rs 788.6 million in the corresponding previous year, recording a spectacular growth of over 128.8%. Net profit after tax for the year is also higher at Rs. 1233.9 million up by 149.5% as against Rs. 494.6 million.
Panacea Biotec has identified brand building in exports as its thrust area and it has significant presence in the global markets including the CIS, Africa, the Middle East and Asia, specifically China, Cambodia, Myanmar, Malaysia, Thailand, Uzbekistan and Bangladesh.Panacea Biotec’s leading brands Nimulid, Nimulid-MD, Nimulid-Transgel, Kondro, Alphadol-C, Panimun Bioral, Toff Plus and Giro enjoy wide prescription across different countries in the overseas market. The company has achieved export turnover to the tune of Rs.148 million during FY 2004-05.
Panacea Biotec is also planning to introduce other branded formulations viz., Ocimix, Glizid-M, Metlong 500 and Nimulid Nugel in the overseas markets besides getting its OTC range of natural & herbal products registered in the existing as well as in new markets.

PRODUCTS:-
Focused research efforts at Panacea Biotec state-of-the-art R&D centers has led to 22 worldwide product patents valid in over 60 countries including developed markets and another 99 patents in the pipeline. The exclusive products based on patented Drug Delivery System include Xeed ( anti-tubercular FDC with innovative Drug Delivery for optimum bioavailability of Rifampicin ), Nimulid Safeinject ( parenteral formulation of Nimesulide based on co –solvent technique ), Panimun Bioral ( Cyclosporine formulation based on SEDDS technology ), ThankGod ( Euphorbia prostrata extract for the comprehensive management of haemorrohoids ), Nimulid MD ( Nimesulide tablets based on the fast dissolving mouth technology ), Willgo ( Nimesulide once a day formulation ), Nimulid Transgel ( Nimesulide transdermal Gel ), Nimcet ( Synergistic combination of Nimesulide once a day + Cetrizine )
The company has launched 43 brands in the domestic and export markets in various therapeutic segments including anti - osteoporosis, anti – diabetics , immuno-suppressants and pain management.
Till the year 2005-06, Panacea Biotec has filed 70 complete and 16 provisional Indian Patent applications and 22 PCT applications. Panacea Biotec has over 277 patent applications filed in India and worldwide, out of which 140 patents have been granted in various countries like USA, Japan, Russia, China, Australia, Canada etc and the remaining are under prosecution in various countries across the globe.
























4) RASI SEEDS



COMPANY BACKGROUND:-

Rasi Seeds was envisioned by Mr.M.Ramasami, and was initiated in the year 1973 in Attur located in Salem District, India. Rasi Seeds has made rapid advances from seed production and supply ventures to a commendable position in Research and Development (R&D) because of the remarkable service of Mr.R.Krishnamurthy, renowned for his extra long staple superfine cotton variety SUVIN and the popular Medium Staple variety LRA 5166.

Having excelled in the Research and Development in cotton seeds, it went on to expand into a multi-crop, multi-location quality research movement and has proved beneficial to the farming community. Our statistics alone stands witness to our quality and success where our R&D product coverage alone measures an impressive figure of over 10 million acres in the past decade.

Rasi Group always looks ahead for any opportunities, which result in the betterment of farming community and the industry. In line with the above company earmarked as group activity the cotton yarn spinning mill Rasi Tex (In) P Ltd to realize the dream of a group with end-to-end solution that is right from development of new cotton seeds to Garments.

Rasi Group also explores the new trends in the industry like the corporate and contract farming, which will provide a win-win solution to Corporate/Farmer, Spinner, Ginner and Seed Company.

Production

In India Rasi is the only hybrid seed company that has emerged to hold direct seed production involving the seed growers of about 10,000 farmers.

To get more productivity and best quality at length pre-season technical meeting is arranged and seed production guidelines will be discussed with young technically qualified field staffs of our production team. An exclusive team is employed to handle crops such as Cotton, Vegetables, Pearl Millet, Maize, Sunflower and Paddy for effective supervision and guidance to seed producing farmers through out the Seed Production period.

Processing

Seed processing is a crucial aspect of seed production. The best of processing machinery and equipment are in place to ensure good quality seeds. The processing personnel are well trained to produce consistent quality, since each lot is from a different seed production farmer.

PRODUCTS:-

Rasi Seeds has done extensive research for crop improvement incorporating latest technology in breeding techniques.


1) Cotton

When the Company launched its first set of cotton research hybrids namely RCH 1 and RCH 2 in the year 1992, the agricultural industry was overwhelmed at the tremendous yield that these hybrids produced.

RCH 2 especially created history by its remarkable yield in farmers’ fields. Rasi Seeds has been the first to engineer Genetic variability to suite various agro climatic zones with wider adoptability by producing hybrids of various staple lengths, high strength and a biotic stress tolerance in cotton.

2) Bt Cotton

Rasi Seeds has released fourteen elite Bt cotton hybrids for commercial cultivation with approval of Genetic Engineering Approval Committee, Ministry of Environment and Forests, Govt. of India. With that Rasi emerged first in the number of Bt cotton released in India. Also many more hybrids are in pipeline to cover different segments in India

3) Paddy

Utmost importance is given to produce high yield, and finest quality of rice with the support of technology. Maintenance Breeding is also major activity to improve and maintain the popular varieties.

4) Pearl Millet

Breeding for high yielding, downy mildew resistant lines with quality grains and fodders to suit the entire pearl millet growing area. Rasi Seeds in collaboration with the International Crops Research Institute for the Semi-Arid Tropics (ICRISAT) is in the process of creating new breeding lines.

5) Maize

A high demand cereal in the poultry and starch industries is being supported by breeding programmes that address quality and yield.Vegetables

6) Vegetables

A narrowed focus on nutritional requirements through vegetables is the pursuit in Rasi for tasteful hybrids of Tomato, Okra, Brinjal, Chilies, Gourds and Cluster Beans.


5) NUZIVEEDU SEEDS


COMPANY BACKGROUND:-

Nuziveedu Seeds Limited was established in the year 1973 with an objective to make good quality seeds of public bred varieties available to the farmers. With strong accent on research by establishing well equipped R & D facilities at Kompally (Biotechnology lab, seed Testing lab, quality lab) and fully irrigated research farms at Hyderabad, Nizamabad, Guntur, Nuziveedu, Gurgoan for plant breeding and evaluation studies, led to the development of the best hybrids of Cotton, Maize, Bajra, Sorghum, Sunflower in the country, which have earned the trust and confidence of the farmers and market. The Brands Subeej brand seeds have become synonyms with quality seeds.

The company is able to compete and grow in the seed industry by maintaining the highest standards in operations, plant breeding, seed production, processing, quality control and seed distribution. The entire R & D activities are supervised by well qualified and competent scientists and other with technical experience.

The company also acquired the most modern machinery for carrying out the operations of Seed processing and packing conveniently and efficiently. The hybrid seeds are produced as per the production programme in contract arrangement with loyal and experienced growers which are processed at well equipped processing plants of the company. The company has well organized GOT farms at Guntur, Nuziveedu, Medak, Nizamabad and Hyderabad for rigorous genetic purity testing.

The rapid pace of scientific development over the part decades in agricultural sector and Biotechnology has emerged as the most effective and significant tool in meeting the challenges of agriculture. NSL has geared up for the future by the establishment of a well equipped Biotechnology laboratory at Kompally.

Business Philosophy

- To develop and maintain the best quality hybrids.

- To maintain extend the quality standards across all products.

- To ensure consistent and timely supply of seeds to the market.

- To maintain harmonious relationship with growers, dealers, distributors and suppliers.

- To create a congenial working atmosphere to enable the employees grow and prosper along with company.

- To inculcate the objectives & philosophy of the company into the employees.






PRODUCTS:-

1) Cotton:-

- NCS-145 (Bunny & Bunny Bt)
- NCS 207 (Mallika & Mallika Bt)
- NCS 138 (Kisan Early)
- NCS 999 (Super Bunny)

2) Sorghum:-

- NSH 27 (Sona)
- NSH 36(Bhagyasree)
- NSH 99 (Bhakti)
- NSH 54 (Mukti)

3) Maize:-

- NMH-589 (Suvarna)
- NMH 145 (Ajay)
- NMH-234 (Kamadhenu)
- NMH-2235 (Vijay)
- NMH-909 (Raja)
- NMH-450 ( Gaga )
- NYMPH 360 ( Krishna )

4) Sunflower:-

- NSFH 36 (Sreshta)
- NSFH - 9 (Mangala)

5) Vegetables:-
- TOMATO:-
- Tomato hybrid Surya
- Tomato hybrid NTS 608
- Tomato hybrid (Jaya)
- BRINJAL:-
- NBH 696
- NBH 750 (Mahanandi)
- NBH 601
- BHENDI (Okra):-
- NBH -225 (Prabava )
- NBH -245
- NB 55 (Srivani)
- CHILLIES:-
- NCH 1233 (Siri)
- NCH 1236(Sampada)

GROWTH:-

FINANCIAL HIGHLIGHTS







INR in Millions
Sl. No.

2000-01 Audited
2001-02 Audited
2002-03 Audited
2003-04 Audited
2004-05 Audited
1
Equity
45
50
50
50
50
2
Reserves
94.97
535.80
901.10
1,428.93
2,220.20
3
Reserves including Deferred Tax
94.97
535.80
916.95
1,444.78
2,220.20
4
Net Worth
139.97
585.80
951.10
1,478.93
2,270.20
5
Fixed Assets
204.74
225.18
531.04
657.85
2,017.88
6
Total Assets
250.40
723.11
1,513.38
2,389.24
4,311.66




















6) NOVONORDISK


COMPANY BACKGROUND:-

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as homeostasis management, growth hormone therapy and hormone replacement therapy.Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.With headquarters in Denmark, Novo Nordisk employs approximately 23,600 full-time employees in 79 countries, and markets its products in 179 countries.Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.
General information :-
Headquarters
Denmark
International
International production facilities in six countries.
Affiliates or offices in 79 countries
Workforce
More than 23,600 employees (Dec 2006).
Approximately 53% of employees are located in Denmark, 47% in the rest of the world (North America: 2,846, Japan & Oceania: 980, International Operations: 4,188, Europe: 2,944, Denmark 12,214).
· 17,4% within research and development
· 35,6% in production and production administration
· 29,6% in international sales and marketing
· 17,4% in administration



·




GROWTH:-

Sales*
38,743
Sales bybusiness segment*
· Diabetes care 27,866
· Biopharmaceuticals 10,877
Turnoverby region*

· Europe 14,708
· Japan & Oceania 4,669
· North America 12,280
· International Operations 7,086

PRODUCTS:-

Product areas
Diabetes care
Haemostasis management (NovoSeven®)
Growth hormone therapy
Hormone replacement therapy (HRT)











7) VENKATESHWARA HATCHERIES


COMPANY BACKGROUND:-
1971, when Padmashree Dr. BV The foundation of the VH Group as well as that of modern Indian poultry industry was laid back in Rao gave shape to his vision by setting up Venkateshwara Hatcheries P. Ltd. - the flagship company of the VH Group.
His pioneering spirit, foresight, and confidence transformed poultry from a backyard activity into an organized, promising industry, ranking amongst the best in the world.
Today, the VH Group is a Rs. 1300 Crore conglomerate, the largest fully integrated poultry group in Asia and offers under one roof, total support for poultry development. The group's greatest success has been its ability to indigenize the Babcock (layer) and Cobb (broiler) breeds, while maintaining world standards in productivity and performance. The genetic research of Venco and VRB, joint ventures of VH Group with Cobb Vantress and ISA Breeder has earned the VH Group many awards and yielded rich dividends to farmers and the Indian economy.
With the Group's nationwide network of 38 layer, 38 broiler associate hatcheries and 156 broiler integrated hatcheries, the Indian farmer can avail of day-old chicks right at his doorstep.

Major Milestones of the VH Group

The group has been first in the country to
- Start pureline research and development in India
- Use Specific Pathogen Free eggs in the manufacture of poultry vaccines
- Produce Specific Pathogen Free eggs in India
- Introduce the concept of combined and inactivated (killed) vaccines
- Introduce processing of chicken and eggs
- Manufacture automated poultry equipment
- Initiate poultry education through the Dr. BV Rao Institute of Poultry Management and
Technology
- Start sophisticated disease diagnostic, surveillance and monitoring laboratories

Dr. BV Rao Institute of Poultry Management and Technology, the Specific Pathogen Free egg production facility, and the Poultry Diagnostic and Research Centre are the only ones of their kind in India.

PRODUCTS:-

Vencobb Broiler and Broiler Breeder
BV-300 Layer and Layer Breeder
Animal Health Products
Poultry Vaccines
SPF Eggs
Incubation Systems
Poultry Farm Equipment
Poultry Feed
Processed Chicken
Egg Powder
Nutritional Health Products Humans
Pet Food and Health Care
De-oiled Cake
Biosecurity Products
Feed Supplements






























8) INDIAN IMMUNOLOGICALS


COMPANY BACKGROUND:-

IIL pursues not only the mandate of NDDB to provide products and services to enhance the quality of livestock in the country but also use its technological capabilities to the benefit of the people of India. IIL strongly believes that its mission of "immunity made affordable" can be actively pursued only with a sound technology base in modern biotechnology.IIL operates a facility in Ooty to manufacture the vero cell culture rabies vaccine for use in human beings. This plant was set up in 1998 at the specific request of the Government of India so that our country can phase out use of the older and unsafe sheep brain vaccine (also termed nerve tissue vaccine - NTV) with themodern tissue culture vaccine.IIL sells the product under the brand name "Abhayrab" through its network of "Abhay Clinics".IIL is the second company in the world to launch the purified vero cell rabies vaccine (PVRV).The vaccine is sold at very economical price when compared to the brands of multinational companies. The success of Abhayrab and Abhay Clinics emboldened IIL to build a new vaccine facility in Hyderabad to manufacture various other human vaccines such as Diphtheria, Pertussis, Tetanus, Recombinant Hepatitis B, Hepatitis A and Measles. This plant will also produce combination vaccine against these diseases.

PRODUCTS:-

1) Human Health - Anti Rabies
- Purified Vero Cell Rabies Vaccine - Abhayrab
- Rabies Antiserum I.P -AbhayRIG 2

2) Human Health > MMR
- Abhay-Vac-3 - Measles, Mumps, Rubella Vaccine EP

3) Human Health > Hepatitis – B
- Elovac-B - Hepatitis – B vaccine I.P. (r DNA)








9) MAHYCO MONSANTO BIOTECH


COMPANY BACKGROUND:-

From modest beginnings nearly a century ago, Monsanto is today a global leader in agricultural solutions.
Monsanto in India has its corporate office at Mumbai and is committed to provide top-quality, cost-effective and integrated approaches for improving farm productivity to produce better quality foods, strictly adhering to stringent standards for eco-care and safety.

Monsanto Company has many revolutionary products and technological breakthroughs in the agricultural sciences to its credit.

PRODUCTS:-

Using Biotechnology to produce high yielding, pest resistant crops

Monsanto's work in India began over 50 years ago, soon after independence. Machete, the first rice herbicide was launched in India in 1975, and still continues to be a leading weed control tool for farmers in western India. Roundup is providing plantation growers with a leading-edge weed control solution since 1991. Roundup has gone on to become an important weed control product for farmers, large and small, throughout the country.

Monsanto is a committed participant in the seed industry. High-yield crop varieties and hybrid crops such as corn, sunflower and cotton are important crops that the company is committed to developing.

Monsanto, through its field operations, knowledge of agricultural production and constant search for new agricultural solutions and technologies, seeks to develop, communicate and provide sustainable solutions to Indian farmers.










10) GLAXOSMITHKLINE


COMPANY BACKGROUND:-

As the second largest pharmaceutical company in the world (after Pfizer), the company had sales of £23.2 billion and made a profit of £7.8 billion in 2006. It employs around 110,000 people worldwide, including over 40,000 in sales and marketing. Its global headquarters are GSK House in Brentford, London, United Kingdom, with its United States headquarters based in Philadelphia and its consumer products division based in the Pittsburgh suburb of Moon Township, Pennsylvania. The research and development division is headquartered in Research Triangle Park (RTP) in North Carolina.

The company is listed on the London and New York stock exchanges. The majority of its activity is in the United States, although the company has a presence in almost 70 countries.

In 2006, pharmaceutical sales accounted for £20.08 billion (or 87%) of GSK's total sales. Sales are based around a broad range of products with the most successful (starting with highest sales) being:

Seretide (Advair in US), a combination of the bronchodilator salmeterol and the steroid fluticasone
Avandia (rosiglitazone), a PPAR-gamma agonist
Lamictal (lamotrigine), an anticonvulsant used to treat various types of epilepsy and type I bipolar disorder
Wellbutrin (bupropion), an anti-depressant
Zofran (ondansetron hydrochloride), used to prevent nausea and vomiting associated with chemotherapy and radiotherapy for cancer
Valtrex (valacyclovir), an antiviral drug used in the management of herpes simplex and herpes zoster (shingles)
Coreg (carvedilol), a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure
Imigran / Imitrex (sumatriptan), a triptan drug including a sulfonamide group for the treatment of migraine.

GLOBAL LOCATIONS:-

Global Pharmaceutical Operations headquarters in Brentford, United Kingdom with US operations based at Franklin Plaza in Philadelphia, Pennsylvania and Research Triangle Park, North Carolina.
Consumer Products headquarters in Moon Township, Pennsylvania suburb of Pittsburgh
Major R&D sites in Greenford,United Kingdom; Stevenage, United Kingdom; Harlow, United Kingdom; Ware, United Kingdom; Beckenham, United Kingdom; Verona, Italy; Zagreb, Croatia; Evreux, France; Research Triangle Park, North Carolina; and Upper Merion and Collegeville, Pennsylvania
Major manufacturing sites for prescription products in Ware, United Kingdom; Evreux, France; Montrose, United Kingdom; Barnard Castle, United Kingdom; Crawley, United Kingdom; Bristol, Tennessee; King of Prussia, Pennsylvania; Zebulon, North Carolina; Cidra, Puerto Rico; Jurong Singapore and Cork Ireland; Parma, Italy.
Major manufacturing sites for consumer products in Maidenhead, United Kingdom; Cork, Ireland; Mississauga, Ontario; Aiken, South Carolina; Clifton, New Jersey; Memphis, Tennessee; and St. Louis, Missouri
GSK has a presence in over 72 countries
Most of the biological part of GSK in Belgium (Wavre and Rixensart)

PRODUCTS:-

Prescription medicines
Our pharmaceutical products include
treatments for asthma, HIV/AIDS,
malaria, depression, migraine, diabetes,
heart failure, digestive conditions
and cancer.

Vaccines
We also market over 25 vaccines to protect against illnesses such as hepatitis A and B, diphtheria, tetanus,
whooping cough, typhoid and influenza.

Over 1300 of our scientists are dedicated to developing new vaccines.


GROWTH:-

Revenue
£23.2 billion (2006)
Net income
£7.8 billion (2006)
Employees
Over 100,728 (2005)

POST GRADUATE DIPLOMA IN BIOTECHNOLOGY MANAGEMENT,PUNE

THE PGDM IN IN PUNE SPECIALLY WITH BIOTECHNOLOGY. PARTICULARLLY IT DEALS WITH THE MANAGEMENT SECTOR WTTH SPECIALY CARPORATE SECTOR IN BIOTECHNOLOGY

ADD;MITCON INSTITUTE OF MANAGEMENT
NEAR CHATRAPATI SHIWAJI SPORTS COMPLEX,
NEAR OCTORI NAKA,BALEWADI,BYPASS HIGHWAY-411045,PUNE ,INDIA


WISH U BEST
SHRIKANT BALDE
PGDM-BIOTECH MANAGEMENT.

THE NEW FIELD THAT YOU EXACTLY WANT

HI,
THE BT MANAGEMENT IS THE EXACTLY WHAT YOU WANT, MEANS THIS IS A PARTICULAR COURSE OF BIOTECHNOLOGY WITH RESPECT TO FIELD OF MANAGEMENT.YOU ALL GOING TO READ MY OPINIONS AND NEW IDIAS ABOUT THIS RESPECTIVE SUBJECT....

SHRIKANT